Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in pulmonary hypertension due to left ventricular systolic dysfunction
CTR20132873Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of riociguat in pulmonary hypertension due to left heart disease (PH-LHD), left ventricular systolic dysfunction (LVSD), ischaemic cardiomyopathy (ICM), dilated cardiomyopathy (DCM), sponsored by Bayer. Started Apr 2014; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension due to left heart disease (PH-LHD)left ventricular systolic dysfunction (LVSD)ischaemic cardiomyopathy (ICM)dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on CTR20132873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132873.